Aprotinin concentration varies significantly according to cardiopulmonary bypass conditions

Okamura, T.; Ishibashi, N.; Iwata, Y.; Zurakowski, D.; Jonas, R. A.
November 2008
Perfusion;Nov2008, Vol. 23 Issue 6, p355
Academic Journal
Although aprotinin is partially excreted unchanged in the urine, its primary site of metabolism is in the renal lysosomes following proximal tubule resorption. This study tested the hypothesis that plasma aprotinin concentration varies with cardiopulmonary bypass conditions. Thirtytwo piglets (weight 13.2 ± 1.9 kg) received an aprotinin initial dose of 30,000 KIU/kg, a maintenance infusion of 10,000 KIU/kg/h, with a cardiopulmonary bypass (CPB) prime of 30,000 KIU/kg. Aprotinin infusion was terminated at the end of CPB and stopped during hypothermic circulatory arrest (HCA). Piglets were randomized to four groups (n = 8 per group): HCA, 60-minute period at 15°C; low-flow (LF), 10 mL/kg/min low-flow CPB at 25°C; full flow (FF), full flow CPB at 37°C; control at 37°C without CPB. Blood samples were collected at 7 time points: after induction of anesthesia (baseline), after initial dose, 10, 50 and 115 min after start of CPB, just before end of CPB and 30 min after CPB. Plasma aprotinin levels were determined by modified functional assays. Aprotinin levels in the control group were significantly lower at each point after start of CPB than all groups with CPB (p < .001). In particular, during the reperfusion period, aprotinin levels were higher in HCA and LF groups than FF group (p < .05). ThroughoutCPB, aprotinin levels in the HCA group remained unchanged (p > .40). Bypass conditions affect plasma aprotinin concentration. Recently reported renal and neurological complications with aprotinin use during CPB may reflect excessive dosing and point to the need for real-time monitoring.


Related Articles

  • Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Ishibashi, N.; Iwata, Y.; Zurakowski, D.; Lidov, H. G. W.; Jonas, R. A. // Perfusion;Mar2009, Vol. 24 Issue 2, p99 

    Background and objective: We have previously reported that administration of aprotinin at a single dose protects the cerebral microcirculation. The current study was designed to identify the optimal dose for protecting the cerebral microcirculation with assessment of neurological and behavioral...

  • Comparison of S100B and NSE Between Cardiac Surgery and Interventional Therapy for Children. Yu Liu; Ying Xu; Da-zhen Li; Yuan Shi; Mao Ye // Pediatric Cardiology;Oct2009, Vol. 30 Issue 7, p893 

    This study aimed to compare the release of S100B and NSE between cardiac surgery and interventional therapy for children and to investigate whether S100B serum concentration correlates with cardiopulmonary bypass in children. For this study, 40 children with congenital heart disease were...

  • Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Pappalardo, F.; Franco, A.; G., G. Crescenzi; Poli, A.; Zangrillo, A.; Koster, A. // Perfusion;Jan2007, Vol. 22 Issue 1, p67 

    Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by...

  • Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass. Parissis, Haralabos // Journal of Cardiothoracic Surgery;2011, Vol. 6 Issue 1, p44 

    A treatment strategy of a difficult and unusual problem is presented. We are reporting a case of a patient who had a documented allergy to heparin and required Cardiac surgery for an ASD closure. The anticoagulation regime used during cardiopulmonary bypass was lepirudin based. This report...

  • Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch, Y. P. J.; Ganushchak, Y. M.; de Jong, D. S. // Perfusion;Jan2006, Vol. 21 Issue 1, p27 

    Background: Accurate control of heparin anticoagulation is necessary during all stages of cardiopulmonary bypass (CPB). The activated clotting time, first described by Hattersley in 1966, is mostly used for determination of anticoagulation. Either celite or kaolin are used as activators. An ACT...

  • Nitric oxide administration during paediatric cardiopulmonary bypass: a randomised controlled trial. James, Christopher; Millar, Johnny; Horton, Stephen; Brizard, Christian; Molesworth, Charlotte; Butt, Warwick // Intensive Care Medicine;Nov2016, Vol. 42 Issue 11, p1744 

    Purpose: Cardiopulmonary bypass induces an ischaemia-reperfusion injury and systemic inflammatory response, which contributes to low cardiac output syndrome following cardiac surgery. Exogenous nitric oxide during cardiopulmonary bypass has shown potential to ameliorate such injury....

  • Editorial. Taylor, K.M. // Perfusion;Mar2005, Vol. 20 Issue 2, p63 

    Comments on the issues concerning the growth in awareness and interest in the systematic inflammation response by cardiopulmonary bypass. Susceptibility of neonates to the inflammatory process; Use of leucocyte inhibition as potential therapeutic strategy in pediatric open-heart surgery; Role of...

  • Effects of protective and conventional mechanical ventilation on pulmonary function and systemic cytokine release after cardiopulmonary bypass. Koner, Ozge; Celebi, Serdar; Balci, Huriye; Cetin, Gurkan; Karaoglu, Kamil; Cakar, Nahit // Intensive Care Medicine;Apr2004, Vol. 30 Issue 4, p620 

    Objective: To evaluate the effects of protective and conventional ventilation with or without positive end-expiratory pressure (PEEP), on systemic tumor necrosis factor-alpha, interleukin-6 levels and pulmonary function during open heart surgery.Design: Prospective,...

  • Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. J. Boldt; Ch. Brosch; K. Röhm; M. Papsdorf; A. Mengistu // BJA: The British Journal of Anaesthesia;Apr2008, Vol. 100 Issue 4, p457 

    Background The effects of hydroxyethylstarch (HES) 130/0.4 6% and gelatin 4% on inflammation, endothelial integrity, and renal function after cardiac surgery were compared. Methods Sixty patients aged >80 yr undergoing cardiac surgery were randomized to receive gelatin (n=30) or HES 130/0.4...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics